Literature DB >> 17685844

Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: an integrated qualitative and quantitative analysis.

Greg Guest1, Laura Johnson, Holly Burke, Reathe Rain-Taljaard, Lawrence Severy, Claire von Mollendorf, Lut Van Damme.   

Abstract

If proven effective, vaginal microbicides and diaphragms will likely be part of a larger HIV prevention model that includes condoms and other prevention strategies. It is, therefore, important to understand how introducing new prevention methods may affect overall patterns of sexual risk behavior. Data presented were collected as part of a safety and feasibility study of ACIDFORM gel with a diaphragm among 120 women in South Africa. Interviews were administered at enrollment and months 1, 3, 5, and 6 of the trial. Focus groups were conducted at trial exit. Frequency of sex increased significantly after enrollment. This increase appears to be owing to perceived protection from HIV and greater sexual pleasure afforded by the gel. Male condom use was high overall but increased significantly from enrollment. Data suggest this is because of increased partner involvement, increased negotiating power afforded by study participation, and provision of free condoms perceived to be of high quality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685844     DOI: 10.1521/aeap.2007.19.4.310

Source DB:  PubMed          Journal:  AIDS Educ Prev        ISSN: 0899-9546


  9 in total

1.  Sexual communication among married couples in the context of a microbicide clinical trial and acceptability study in Pune, India.

Authors:  Heather M Marlow; Elizabeth E Tolley; Rewa Kohli; Sanjay Mehendale
Journal:  Cult Health Sex       Date:  2010-11

2.  User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.

Authors:  Kathleen M Morrow; Kristen Underhill; Jacob J van den Berg; Sara Vargas; Rochelle K Rosen; David F Katz
Journal:  Arch Sex Behav       Date:  2014-01-23

3.  Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations.

Authors:  J T Galea; J J Kinsler; X Salazar; S-J Lee; M Giron; J N Sayles; C Cáceres; W E Cunningham
Journal:  Int J STD AIDS       Date:  2011-05       Impact factor: 1.359

4.  Perceptions of sexual risk compensation following posttrial HIV vaccine uptake among young South Africans.

Authors:  Catherine L Macphail; Jennifer N Sayles; William Cunningham; Peter A Newman
Journal:  Qual Health Res       Date:  2012-01-04

5.  Effect of acculturation on the acceptability of potential microbicides and sexual risk-taking.

Authors:  Andrea Ries Thurman; Alan E C Holden; Rochelle N Shain; Sondra Perdue; Jeanna M Piper
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

6.  The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.

Authors:  Mitzy Gafos; Robert Pool; Misiwe Adelaide Mzimela; Hlengiwe Beauty Ndlovu; Sheena McCormack; Jonathan Elford
Journal:  AIDS Behav       Date:  2014-02

7.  Acceptability and use of the diaphragm and Replens lubricant gel for HIV prevention in Southern Africa.

Authors:  Elizabeth T Montgomery; Helen Cheng; Ariane van der Straten; Agnes C Chidanyika; Naomi Lince; Kelly Blanchard; Gita Ramjee; Busisiwe Nkala; Nancy S Padian
Journal:  AIDS Behav       Date:  2009-09-10

8.  Pregnancy in HIV clinical trials in Sub Saharan Africa: failure of consent or contraception?

Authors:  Agnes Ssali; Stella Namukwaya; Leonard Bufumbo; Janet Seeley; David G Lalloo; Anatoli Kamali; Rosalind Parkes-Ratanshi
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 9.  Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.

Authors:  Elizabeth G Doggett; Michele Lanham; Rose Wilcher; Mitzy Gafos; Quarraisha A Karim; Lori Heise
Journal:  J Int AIDS Soc       Date:  2015-12-21       Impact factor: 5.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.